Biogen scraps Alzheimer drug trials, wiping $17 billion off its market value
March 21, 2019 at 10:19 AM EDT
Biogen and partner Eisai Co Ltd are ending two late-stage trials for the experimental Alzheimer's drug aducanumab, in a setback to efforts to find treatments for the disease and for Biogen's stock, which lost more than $17 billion of its value on Thursday.